NCT00918580 - Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease | Biotech Hunter

Enrollment

158

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions

Pneumococcal Conjugate Vaccine

Interventions

BIOLOGICAL

13-valent Pneumoccocal Conjugate Vaccine

2 doses of 13vPnC will be administered by intramuscular injection separated by approximately 6 months.

Trial Locations (19)

Pfizer Investigational Site, Orbassano (TO)

Pfizer Investigational Site, The Bronx

Pfizer Investigational Site, Cairo

Pfizer Investigational Site, Cairo

Pfizer Investigational Site, Birmingham

Pfizer Investigational Site, Nashville

Pfizer Investigational Site, Louisville

Pfizer Investigational Site, Paris

Pfizer Investigational Site, Louisville

Pfizer Investigational Site, Roma

Pfizer Investigational Site, Beirut

Pfizer Investigational Site, Beirut

Pfizer Investigational Site, Riyadh